NOVEL GLP-1 RECEPTOR AGONISTS: RETATRUTIDE, CAGRILLINTIDE, TIRZEPATIDE, AND SEMAGLUTIDE

The pharmaceutical landscape witnessing a revolution with the emergence of novel glucagon-like peptide-1 (GLP-1) receptor agonists. These innovative drugs demonstrate immense potential in managing type 2 diabetes and, progressively, are being explored for their therapeutic benefits in other conditions like obesity and cardiovascular disease. Among